Pharmalytica^SM

Leadership Team

Our leadership team is comprised of representatives from the core areas of strategic development, technical and regulatory development, laboratory operations and marketing. Leadership team members are dedicated to providing our clients with expert services at the highest level of quality in the industry. Team members are also committed to providing the employees of NSF Pharmalytica with a rewarding growth environment that is both challenging and fun.

• James R. Scull, Ph.D.
  General Manager, NSF Pharmalytica
  jscull@nsf.org
• Richard C. Wedlich, M.S.
  Director of Quality Assurance, NSF Pharmalytica
  rwedlich@nsf.org
• Kurt L. Moyer, Ph.D.
  Director of Research
  kmoyer@nsf.org

Team member biographies are provided below:

James R. Scull, Ph.D.
General Manager, NSF Pharmalytica

Dr. James Scull has more than 24 years of pharmaceutical development experience spanning all areas from discovery support to Phase III clinical trials. His current responsibilities include providing strategic scientific and technical leadership with a global perspective to NSF Pharmalytica, part of NSF's Health Sciences Division. Dr. Scull is focused on providing clients with technical expertise and project management designed to accelerate the drug development process. Dr. Scull's primary expertise is in the areas of GLP analytical chemistry, formulation, compliance and separation science. He is also an expert in conducting extractable & leachable studies and oliognulceotide analysis. Prior to joining NSF Pharmalytica, Dr. Scull served as Executive Director of Pharmalytica Services, LLC, Principal Research Scientist for the DuPont Pharmaceutical Company and GLP Outsourcing Manager for Purdue Pharma. Dr. Scull holds a Ph.D. in Analytical Chemistry from Villanova University.

Richard C. Wedlich, M.S.
Director of Quality Assurance, NSF Pharmalytica

Mr. Richard C. Wedlich has 25 years R&D experience spread out over the pharmaceutical, chemical and aerospace industries. He is presently director of Quality Assurance for NSF Pharmalytica (Bristol, CT). Prior to joining NSF Pharmalytica, Mr. Wedlich was principal and co-founder of Pharmalytica Services, LLC (Bristol, CT), where he served as vice-president and executive director of Quality Assurance and Regulatory Affairs for over 10 years. Still prior to that, he was senior engineer at the Schering-Plough Research Institute (Union, NJ), senior process safety specialist at Chilworth Technologies (Princeton, NJ), senior research chemist at Olin Corporation (Cheshire, CT), scientist at Lockheed Engineering, Management and Sciences Company (NASA WSTF) and chemist at Organon Pharmaceuticals (West Orange, NJ). Mr. Wedlich has published numerous peer-reviewed, scientific articles. He holds a BS in chemistry from Ramapo College of New Jersey and an MS in chemistry from Marquette University.

Kurt L. Moyer, Ph.D.
Director of Research

Dr. Moyer has more than 20 years of pharmaceutical development experience spanning all areas from discovery support to marketed products. His primary expertise is in the areas of bioanalysis, extractables and leachables, method development and validation, identification of impurities and metabolites, and GLP/GMP compliance. He also has extensive experience with drugs for anticoagulant and cardiovascular therapies. In addition, Dr. Moyer provides NSF Pharmalytica clients with project management that is designed to accelerate the development process. Prior to joining NSF Pharmalytica, Dr. Moyer served as a Senior Research Investigator for Sanofi Aventis and a Research Scientist for the DuPont Pharmaceutical Company. Dr. Moyer received his Ph.D. in Biochemistry from Villanova University.